SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion

Zulassung für Omikron? 😂😂😂 Man bracht keine Masken mehr und Sorrento kommt mit der Zulassung für Omikron 😂😂😂

Da muss du an Dir aber noch ganz schwer daran arbeten...!!!

Ich weiß.. Ich passe mich euer/ dein Niveau an!!

Deine Posts sind aber kein bisschen besser...

Isch Lirumschen!!! 1 Abschied und 1 Nick reicht schon... Ist eh alles Sinnlos was du Postest 🥱🥱

Reverse Split

Wird heute die Dollar Marke durchbrochen? Wie gehts dann weiter? Was würde jetzt Nuaberzu sagen

Juppp sieht man am Kurs... Sofort über 5% runter🤣🤣🤣

Das klingt ja fantastisch 😅

https://www.globenewswire.com/news-release/2022/12/06/2568404/0/en/Sorrento-Therapeutics-has-Received-FDA-Clearance-to-Initiate-Clinical-Trials-with-a-Next-Generation-mRNA-STI-1557-Vaccine-Against-Omicron-SARS-CoV-2-Virus.html

Sorrento muss 173,5 Millionen Dollar an ImmunityBio zahlen. Also um korrekt zu sein, 156,8 Millionen und der Rest geht an Nantibody.

On December 2, 2022, the arbitrator executed a final award in the aggregate amount of $173.5 million for Sorrento’s breaches of both license agreements, of which $156.8 million is payable to the Company and the remainder is payable to NANTibody, the Company’s subsidiary. In addition, the arbitrator determined that the Claimants are entitled to declaratory relief that both license agreements remain in full force and effect, with respect to ImmunityBio’s PD-L1 NK cell. The arbitrator further declared that Sorrento and Claimants have no further rights or obligations under either license agreement with respect to other targets. Sorrento has no further obligation to contribute materials or know how with respect to the PD-LI antibody, and Claimants are not required to return any materials or know how received from Sorrento.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1326110/000132611022000076/ibrx-20221202.htm

https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-phase-ii-results-pd-l1-checkpoint